# Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

> **NCT05214573** · — · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 386301 (actual)

## Conditions studied

- Type 2 Diabetes
- Cardiac Disease

## Interventions

- **DRUG:** Glucagon like peptide 1 receptor agonist
- **DRUG:** Sodium-glucose cotransporter 2 inhibitor
- **DRUG:** Dipeptidyl Peptidase 4 Inhibitor
- **DRUG:** Sulfonylurea

## Key facts

- **NCT ID:** NCT05214573
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2025-07-22
- **Target enrollment:** 386301 (ACTUAL)
- **Last updated:** 2025-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05214573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05214573, "Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05214573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*